Cantor Fitzgerald analyst Pablo Zuanic maintains SNDL (NASDAQ:SNDL) with a Neutral and raises the price target from $3.56 to $3.6.
The Latest Analyst Ratings for Akebia Therapeutics
Akebia Therapeutics (NASDAQ:AKBA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…